Trial Profile
Early Treatment of Borderline Pulmonary Arterial Hypertension Associated with Systemic Sclerosis (SSc-APAH)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Ambrisentan (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms EDITA
- 20 Dec 2017 Status changed from recruiting to completed.
- 30 Oct 2014 New trial record